Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value
$0.91−0.08 (-7.64%)
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Lineage Cell Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Lineage Cell Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $21.06M, up 63.1% year over year. For fiscal 2025 it was $17.73M, up 42.2% from the year before. Over ten years it grew -8.4% a year on average. The highest annual figure on record is $42.60M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.73M | +42.2% |
| FY2024 | Dec 31, 2024 | $12.47M | -20.6% |
| FY2023 | Dec 31, 2023 | $15.71M | +12.3% |
| FY2022 | Dec 31, 2022 | $13.99M | -58.8% |
| FY2021 | Dec 31, 2021 | $33.91M | +175.3% |
| FY2020 | Dec 31, 2020 | $12.32M | -31.4% |
| FY2019 | Dec 31, 2019 | $17.95M | -14.3% |
| FY2018 | Dec 31, 2018 | $20.96M | -12.8% |
| FY2017 | Dec 31, 2017 | $24.02M | -33.5% |
| FY2016 | Dec 31, 2016 | $36.11M | -15.3% |
| FY2015 | Dec 31, 2015 | $42.60M | +13.5% |
| FY2014 | Dec 31, 2014 | $37.53M | +41.1% |
| FY2013 | Dec 31, 2013 | $26.61M | +46.9% |
| FY2012 | Dec 31, 2012 | $18.12M | +32.2% |
| FY2011 | Dec 31, 2011 | $13.70M | +67.2% |
| FY2010 | Dec 31, 2010 | $8.19M | – |
| FY2009 | Dec 31, 2009 | -$3.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.82M | +16.7% |
| Q2 FY2026 | Jun 30, 2026 | $4.77M | +53.7% |
| Q1 FY2026 | Mar 31, 2026 | $4.23M | +36.0% |
| Q4 FY2025 | Dec 31, 2025 | $8.24M | +140.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.27M | +3.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.11M | +8.3% |
| Q1 FY2025 | Mar 31, 2025 | $3.11M | +3.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.42M | -12.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.17M | -15.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.87M | -25.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.01M | -28.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.91M | -4.8% |
| Q3 FY2023 | Sep 30, 2023 | $3.74M | +4.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.87M | +17.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.19M | +40.1% |
| Q4 FY2022 | Dec 31, 2022 | $4.10M | -83.4% |
| Q3 FY2022 | Sep 30, 2022 | $3.59M | +27.8% |
| Q2 FY2022 | Jun 30, 2022 | $3.30M | +12.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.99M | -12.0% |
| Q4 FY2021 | Dec 31, 2021 | $24.78M | +850.4% |
| Q3 FY2021 | Sep 30, 2021 | $2.81M | -21.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.93M | +4.5% |
| Q1 FY2021 | Mar 31, 2021 | $3.39M | +1.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.61M | -25.2% |
| Q3 FY2020 | Sep 30, 2020 | $3.57M | -16.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.81M | -46.4% |
| Q1 FY2020 | Mar 31, 2020 | $3.34M | -32.7% |
| Q4 FY2019 | Dec 31, 2019 | $3.49M | -7.8% |
| Q3 FY2019 | Sep 30, 2019 | $4.27M | -12.6% |
| Q2 FY2019 | Jun 30, 2019 | $5.24M | -17.7% |
| Q1 FY2019 | Mar 31, 2019 | $4.96M | -16.4% |
| Q4 FY2018 | Dec 31, 2018 | $3.78M | -19.5% |
| Q3 FY2018 | Sep 30, 2018 | $4.88M | -25.6% |
| Q2 FY2018 | Jun 30, 2018 | $6.36M | +1.4% |
| Q1 FY2018 | Mar 31, 2018 | $5.94M | -8.6% |
| Q4 FY2017 | Dec 31, 2017 | $4.70M | -33.0% |
| Q3 FY2017 | Sep 30, 2017 | $6.56M | – |
| Q2 FY2017 | Jun 30, 2017 | $6.27M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.01M | – |
See a number that looks wrong?